Skip to main content

Table 1 Baseline clinical characteristics (n=20)

From: Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients

Characteristic

No. of patients

%

Age, years

  

  Median

62

 

  Range

31-77

 

Gender

  

  Male

12

60

  Female

8

40

Ethnicity

  

  European

15

75

  Maori

3

15

  Asian

2

10

ECOG 1 status

  

  0

14

70

  1

6

30

Tumor stage

  

  2

1

5

  3

11

55

  4

8

40

Chemotherapy regimen

  

  XELOX2

16

80

  modified FOLFOX63

4

20

Neurotoxicity risk factors

  

  None

17

85

  Diabetes

2

10

  Spinal injury

1

5

  1. 1ECOG, Eastern Cooperative Oncology Group.
  2. 2XELOX, 2-hour infusion of oxaliplatin (130 mg/m2) followed by oral capecitabine (1250 mg/m2) twice daily day 1 to day 14 every 3 weeks.
  3. 3FOLFOX6, 2-hour infusion of oxaliplatin (85 mg/m2) together with 2-hour infusion of leucovorin (400 mg/m2) followed by a fluorouracil bolus (400 mg/m2) and 46-hour infusion (2,400 mg/m2) every 2 weeks.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us